目的 探討艾普拉唑序貫療法對消化性潰瘍患者治療效果及血清學(xué)指標的影響。方法 選取2015年10月—2019年4月河南省人民醫(yī)院省直二院584例消化性潰瘍患者作為研究對象，根據(jù)治療方法的不同將患者分為對照組（n=193）和觀察組（n=391）。對照組口服奧美拉唑腸溶膠囊，20 mg/次，1次/d；克拉霉素膠囊，0.5 g/次，1次/d；呋喃唑酮片，0.1 g/次， 1次/d。觀察組口服艾普拉唑腸溶片，5 mg/次，2次/d；克拉霉素膠囊0.5 g/次，1次/d；連續(xù)治療5 d后再次口服艾普拉唑腸溶片，5 mg/次，2次/d；呋喃唑酮片0.1 g/次，1次/d。兩組患者均連續(xù)治療10 d。觀察兩組患者的臨床療效和幽門螺旋桿菌（Hp）陽性率，同時比較兩組治療前后的血管內(nèi)皮生長因子（VEGF）、堿性成纖維細胞生長因子（bFGF）、一氧化氮（NO）、白細胞介素-17（IL-17）和胃泌素（Gas）水平。結(jié)果 治療后，觀察組治療總有效率為95.91%，顯著高于對照組的80.31%（P<0.05）。治療后，兩組的VEGF、bFGF水平明顯升高，NO及IL-17水平明顯降低（P<0.05），且觀察組各指標改善較對照組更為顯著（P<0.05）。治療后，兩組的Gas水平及Hp陽性率均明顯降低（P<0.05），且觀察組Gas水平和Hp陽性率均顯著低于對照組（P<0.05）。結(jié)論 艾普拉唑序貫療法可有效清除Hp，降低血清胃泌素水平及局部炎性反應(yīng)，療效安全顯著，對促進消化性潰瘍患者病情康復(fù)具有積極意義。

Objective To investigate the effect of ilaprazole sequential therapy on treatment effect and serological index of peptic ulcer patients. Methods A total of 584 patients with peptic ulcer in the The Second Hospital of Henan Provincial People's Hospital from October 2015 to April 2019 were selected as research objects and divided into control group (n=193) and observation group (n=391) according to different treatment methods. Patients in the control group were po administered with Omeprazole Enteric-Coated Capsules, 20 mg/time, once daily; Clarithromycin Capsules, 0.5 g/time, once daily; and Furazolidone Tablets 0.1 g/time, once daily. Patients in the observation group were po administered with Ilaprazole Enteric-coated Tablets, 5 mg/time, twice daily; Clarithromycin Capsules, 0.5 g/time, once daily. After continuous treatment for 5 days, Ilaprazole Enteric-coated Tablets were taken orally again, 5 mg/time, twice daily, and Furazolidone Tablets 0.1 g/time for once daily. Both groups received continuous treatment for 10 days. After treatment, the clinical efficacy and Helicobacter pylori positive rate in two groups were observed, and the levels of VEGF, bFGF, NO, IL-17, and Gas before and after treatment were compared. Results After treatment, the total effective rate of the observation group was 95.91%, which was significantly higher than 80.31% of the control group (P<0.05). After treatment, the levels of VEGF and bFGF in two groups were significantly increased, while the levels of NO and IL-17 were significantly decreased (P<0.05), and the improvement of indicators in the observation group was more significant than those in the control group (P<0.05). After treatment, Gas level and Hp positive rate in both groups were significantly reduced (P<0.05), and Gas level and Hp positive rate in the observation group were significantly lower than those in the control group (P<0.05). Conclusion Ilaprazole sequential therapy can effectively remove Hp, reduce serum gastrin level, and local inflammatory reaction, with safe and significant efficacy, and has positive significance in promoting the recovery of patients with peptic ulcer.

R975

河南省醫(yī)學(xué)科技攻關(guān)計劃項目（201302012）